Journal Article
. 2016 Jan; 10(5):3286-3292.
doi: 10.3892/ol.2015.3655.

Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor

Masahiro Ohara 1 Etsushi Akimoto 1 Midori Noma 1 Kazuo Matsuura 1 Mihoko Doi 2 Naoki Kagawa 3 Toshiyuki Itamoto 1 
Affiliations
  • PMID: 26722327
  •     34 References
  •     4 citations

Abstract

Aromatase inhibitors have played a central role in endocrine therapy for the treatment of estrogen receptor (ER)-positive breast cancer in postmenopausal patients. However, prognostic factors for recurrence following such treatment have not been identified. The current study aimed to validate the prognostic value of endocrine-related progesterone receptor (PgR) status combined with body mass index (BMI). Among 659 consecutive patients with primary breast cancer who underwent curative surgery between 2002 and 2012, 184 postmenopausal patients with ER-positive (ER+) and human epidermal growth factor receptor type 2-negative (HER2-) breast cancer who were treated with adjuvant aromatase inhibitor therapy were assessed. The patients were assigned to groups based on BMI, according to the WHO cut-off value: ≥25 kg/m2 (high, H) or <25 kg/m2 (low, L). Positive nodal status, negative PgR status, BMI-H and a high Ki-67 labeling index (≥20%) were found to be significantly associated with a short recurrence-free interval (RFI) upon univariate analysis (P=0.048, 0.007, 0.027, and 0.012, respectively). The patients were further grouped based on their combined PgR/BMI status. The RFI was significantly shorter in the PgR- and/or BMI-H group compared with that of the PgR+/BMI-L group (P=0.012). Multivariate analysis revealed PgR- tumors and/or BMI-H and positive nodal status to be independent prognostic factors (P=0.012 and 0.020, respectively). The present findings indicate that PgR/BMI status may serve as a practical tool in the management of ER+ and HER2- breast cancer in patients treated with adjuvant aromatase inhibitors.

Keywords: aromatase inhibitor; body mass index; breast cancer; progesterone receptor.

Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole.
V Sini, G Lunardi, +15 authors, L Del Mastro.
Br J Cancer, 2014 Jan 23; 110(5). PMID: 24448359    Free PMC article.
Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.
M A N Sendur, S Aksoy, N Zengin, K Altundag.
Br J Cancer, 2012 Oct 27; 107(11). PMID: 23099804    Free PMC article.
Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Elizabeth J Folkerd, J Michael Dixon, +2 authors, Mitch Dowsett.
J Clin Oncol, 2012 Jul 18; 30(24). PMID: 22802308
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience.
G Berclaz, S Li, +17 authors, International Breast Cancer Study Group.
Ann Oncol, 2004 May 21; 15(6). PMID: 15151943
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Ivana Sestak, Wolfgang Distler, +3 authors, Jack Cuzick.
J Clin Oncol, 2010 Jun 16; 28(21). PMID: 20547990
Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
G Pfeiler, R Königsberg, +9 authors, P Dubsky.
Br J Cancer, 2013 Sep 05; 109(6). PMID: 24002592    Free PMC article.
Estrogen receptor-positive breast cancer in Japanese women: trends in incidence, characteristics, and prognosis.
H Yamashita, H Iwase, +6 authors, S Kobayashi.
Ann Oncol, 2010 Dec 02; 22(6). PMID: 21119029
Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor.
K B Horwitz, W L McGuire.
J Biol Chem, 1978 Apr 10; 253(7). PMID: 632265
Highly Cited.
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
A Goldhirsch, J N Ingle, +4 authors, Panel members.
Ann Oncol, 2009 Jun 19; 20(8). PMID: 19535820    Free PMC article.
Highly Cited.
Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Per Eystein Lønning, Benjamin P Haynes, Mitch Dowsett.
Eur J Cancer, 2014 Feb 11; 50(6). PMID: 24507547
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Mitch Dowsett, Craig Allred, +17 authors, Aman Buzdar.
J Clin Oncol, 2008 Jan 30; 26(7). PMID: 18227529
Highly Cited.
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
Marianne Ewertz, Kathryn P Gray, +14 authors, Henning T Mouridsen.
J Clin Oncol, 2012 Oct 10; 30(32). PMID: 23045588    Free PMC article.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
A Goldhirsch, E P Winer, +5 authors, Panel members.
Ann Oncol, 2013 Aug 07; 24(9). PMID: 23917950    Free PMC article.
Highly Cited.
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
G Viale, M M Regan, +17 authors, BIG 1-98 Collaborative and International Breast Cancer Study Groups.
Ann Oncol, 2011 Feb 22; 22(10). PMID: 21335417    Free PMC article.
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
Harold J Burstein, Ann Alexis Prestrud, +16 authors, American Society of Clinical Oncology.
J Clin Oncol, 2010 Jul 14; 28(23). PMID: 20625130    Free PMC article.
Highly Cited. Systematic Review.
Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.
John M S Bartlett, Cassandra L Brookes, +15 authors, Daniel Rea.
J Clin Oncol, 2011 Mar 23; 29(12). PMID: 21422407    Free PMC article.
Obesity and endocrine therapy: host factors and breast cancer outcome.
Pamela J Goodwin.
Breast, 2013 Oct 01; 22 Suppl 2. PMID: 24074791
Review.
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
M Dowsett, J Houghton, +5 authors, M Baum.
Ann Oncol, 2006 Feb 25; 17(5). PMID: 16497822
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
D C Allred, J M Harvey, M Berardo, G M Clark.
Mod Pathol, 1998 Mar 21; 11(2). PMID: 9504686
Highly Cited. Review.
Usefulness of body mass index as a sufficient adiposity measurement for sex hormone concentration associations in postmenopausal women.
Somdat Mahabir, David J Baer, +5 authors, Philip R Taylor.
Cancer Epidemiol Biomarkers Prev, 2006 Dec 14; 15(12). PMID: 17164376
Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer.
K M Elliott, J Dent, +4 authors, C Palmieri.
Br J Surg, 2014 Apr 02; 101(8). PMID: 24687409
Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer.
Hirotaka Iwase.
Breast Cancer, 2008 Sep 24; 15(4). PMID: 18810576
Review.
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.
WHO Expert Consultation.
Lancet, 2004 Jan 17; 363(9403). PMID: 14726171
Highly Cited. Review.
Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women.
S E Hankinson, W C Willett, +5 authors, F E Speizer.
J Natl Cancer Inst, 1995 Sep 06; 87(17). PMID: 7658481
Highly Cited.
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, +9 authors, L Norton.
N Engl J Med, 2001 Mar 15; 344(11). PMID: 11248153
Highly Cited.
Adiposity and sex hormones in postmenopausal breast cancer survivors.
Anne McTiernan, Kumar B Rajan, +7 authors, Rachel Ballard-Barbash.
J Clin Oncol, 2003 May 14; 21(10). PMID: 12743149    Free PMC article.
Hormone dependency in N-nitrosomethylurea-induced rat mammary tumors.
B M Arafah, H M Finegan, +2 authors, O H Pearson.
Endocrinology, 1982 Aug 01; 111(2). PMID: 7094887
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
F Cardoso, N Harbeck, +3 authors, ESMO Guidelines Working Group.
Ann Oncol, 2012 Nov 20; 23 Suppl 7. PMID: 22997442
Highly Cited.
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight.
Cathrin Brisken.
Nat Rev Cancer, 2013 May 25; 13(6). PMID: 23702927
Highly Cited. Review.
Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
Masahiro Ohara, Hideo Shigematsu, +5 authors, Morihito Okada.
Breast, 2013 Jun 13; 22(5). PMID: 23756383
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
A Goldhirsch, J H Glick, +4 authors, Panel members.
Ann Oncol, 2005 Sep 09; 16(10). PMID: 16148022
Highly Cited.
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.
A Goldhirsch, W C Wood, +4 authors, 10th St. Gallen conference.
Ann Oncol, 2007 Aug 07; 18(7). PMID: 17675394
Highly Cited. Review.
p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study.
Kazuharu Kai, Reiki Nishimura, +2 authors, Hirotaka Iwase.
Int J Clin Oncol, 2006 Dec 21; 11(6). PMID: 17180510
Significance of lung biopsy for the definitive diagnosis of lung nodules in breast cancer patients.
Kazuo Matsuura, Toshiyuki Itamoto, +7 authors, Morihito Okada.
Mol Clin Oncol, 2018 Feb 13; 8(2). PMID: 29435285    Free PMC article.
Optimal body mass index cut-point for predicting recurrence-free survival in patients with non-muscle-invasive urothelial carcinoma of bladder.
Satoru Yonekura, Fumihito Terauchi, +2 authors, Shigeo Kawai.
Oncol Lett, 2018 Aug 22; 16(3). PMID: 30128027    Free PMC article.
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis.
Elizabeth M Salvo, Abril Oliva Ramirez, +4 authors, Imtiaz A Samjoo.
Breast, 2021 Mar 08; 57. PMID: 33677313    Free PMC article.
Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk.
Weiqiang Li, Robert J Klein.
Prostate Cancer Prostatic Dis, 2020 Nov 22; 24(2). PMID: 33219367